STOCK DUELS
AstraZeneca vs Eli Lilly - Official head-to-head comparisons for widely followed pairs.
Official Stock Duel · AZN/LLYPublished
AstraZeneca vs Eli Lilly
Compares AstraZeneca and Eli Lilly across growth, profitability, cash generation, valuation and balance-sheet signals.
Left side
AZN.LSE
Right side
LLY
Comparison categories
6
Generated: Sep 9, 2026, 04:31 AM
Data as of: 2026-09-08
Stock Duels· 23 analyses
Official head-to-head comparisons for widely followed pairs.
Head-to-Head
AZN
AstraZeneca PLC
2VS4
metrics
LLY
Eli Lilly and Company
9.32%
Sales Growth
49.58%
22.78%
Return on Equity (ROE)
102.43%
15.02%
Return on Invested Capital (ROIC)
33.94%
$8.4B
Free Cash Flow
$20.1B
24.05
Price to Earnings (P/E)
37.7
13.61
EV/EBITDA
29.9
Datafin’s View
Two pharma momentum stories: AstraZeneca’s oncology depth against Eli Lilly’s obesity-driven surge.
A diversified pipeline or the momentum of a single mega-product — two routes to growth in pharma. AstraZeneca’s depth in oncology spreads its risk across many shots on goal, while Eli Lilly rides an extraordinary obesity-driven surge that concentrates both the upside and the expectations.
This analysis is for informational purposes only and is not investment advice; it is a repeatable research starting point using the same rules.
Factor Profile
AZN.LSE and LLY are compared inside each metric family.
Results
Latest published or live-generated results from the official Datafin analysis.
| # | Stock | Winner | Sales Growth | Return on Equity(ROE) | Return on Invested Capital(ROIC) | Free Cash Flow | Price to Earnings(P/E) | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 🇬🇧 | AZN.LSE AstraZeneca PLC | - | 9.32% | 22.78% | 15.02% | $8.4B | 24.05 | 13.61 |
| 2 | 🇺🇸 | LLY.US Eli Lilly and Company | 49.58% | 102.43% | 33.94% | $20.1B | 37.7 | 29.9 |
1🇬🇧
AZN.LSE
AstraZeneca PLC
- Sales Growth
- 9.32%
- Return on Equity(ROE)
- 22.78%
- Return on Invested Capital(ROIC)
- 15.02%
- Free Cash Flow
- $8.4B
- Price to Earnings(P/E)
- 24.05
- EV/EBITDA
- 13.61
2🇺🇸
LLY.US
Eli Lilly and Company
- Sales Growth
- 49.58%
- Return on Equity(ROE)
- 102.43%
- Return on Invested Capital(ROIC)
- 33.94%
- Free Cash Flow
- $20.1B
- Price to Earnings(P/E)
- 37.7
- EV/EBITDA
- 29.9
Methodology
Revenue Growthhigher is better
ROEhigher is better
ROIChigher is better
Free Cash Flowhigher is better
P/Elower is better
EV/EBITDAlower is better
Last 5 Updates
Sep 9, 2026, 04:31 AM2 companies
List unchanged (refreshed).
Aug 28, 2026, 04:34 AM2 companies
List unchanged (refreshed).
Aug 17, 2026, 04:33 AM2 companies
Entered:AZN.LSE
Exited:AZN.ST
Aug 6, 2026, 04:32 AM2 companies
List unchanged (refreshed).
Jul 26, 2026, 04:31 AM2 companies
List unchanged (refreshed).